Patents by Inventor William R. Jacobs, Jr.
William R. Jacobs, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11987805Abstract: A genetically modified mammalian cell and genetically modified mammalian cell line comprise a recombination sequence inserted in a target locus on a chromosome of the mammalian cell genome, wherein the recombination sequence comprises Bxb1attB sequence from Mycobacterium smegmatis. A transgenic mammalian cell and transgenic mammalian cell line comprise a heterologous nucleic acid stably integrated in a target locus on a chromosome of the mammalian genome, wherein the heterologous nucleic comprises a heterologous gene configured for expression by the transgenic mammalian cell.Type: GrantFiled: September 24, 2021Date of Patent: May 21, 2024Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINEInventors: William R. Jacobs, Jr., Lawrence Leung, Regy Lukose, Anna Paula de Oliveira
-
Patent number: 11666648Abstract: Provided are attenuated strains of M. tuberculosis and M. bovis BCG which are double auxotrophic mutants with genes knocked out in the biosynthetic pathways for arginine and methionine, and compositions and methods of use thereof.Type: GrantFiled: August 15, 2019Date of Patent: June 6, 2023Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINEInventors: William R. Jacobs, Jr., Sangeeta Tiwari
-
Publication number: 20220162291Abstract: Provided are antibodies and antigen-binding fragments which bind to herpes simplex virus-2 (HSV-2), methods of use employing the antibodies and/or antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and/or antigen-binding fragments.Type: ApplicationFiled: March 19, 2020Publication date: May 26, 2022Inventors: Betsy C. HEROLD, Garnett KELSOE, Masayuki KURAOKA, Clare BURN, William R. Jacobs, Jr.
-
Publication number: 20220090146Abstract: A genetically modified mammalian cell and genetically modified mammalian cell line comprise a recombination sequence inserted in a target locus on a chromosome of the mammalian cell genome, wherein the recombination sequence comprises Bxb1attB sequence from Mycobacterium smegmatis. A transgenic mammalian cell and transgenic mammalian cell line comprise a heterologous nucleic acid stably integrated in a target locus on a chromosome of the mammalian genome, wherein the heterologous nucleic comprises a heterologous gene configured for expression by the transgenic mammalian cell.Type: ApplicationFiled: September 24, 2021Publication date: March 24, 2022Inventors: William R. Jacobs, Jr., Lawrence Leung, Regy Lukose, Anna Paula de Oliveira
-
Publication number: 20210170008Abstract: Provided are attenuated strains of M. tuberculosis and M. bovis BCG which are double auxotrophic mutants with genes knocked out in the biosynthetic pathways for arginine and methionine, and compositions and methods of use thereof.Type: ApplicationFiled: August 15, 2019Publication date: June 10, 2021Inventors: William R. JACOBS, JR., Sangeeta TIWARI
-
Publication number: 20160298165Abstract: The present invention addresses a need for improved methods of treating M. tuberculosis infection using enhancers of respiration, and compositions for treating tuberculosis as well as assays for identifying novel agents for treating M. tuberculosis infection.Type: ApplicationFiled: April 25, 2014Publication date: October 13, 2016Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.Inventors: Travis Hartman, Michael Berney, William R Jacobs, JR., Catherine Vilheze
-
Patent number: 8591918Abstract: Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant mycobacterium, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal.Type: GrantFiled: March 10, 2008Date of Patent: November 26, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Kari Sweeney, Dee Dao, Steven A. Porcelli, John Chan, Tsungda Hsu
-
Patent number: 8455214Abstract: The present invention provides methods for determining a putative antibacterial, the methods comprising determining whether the putative antibacterial inhibits GlgE or Rv3032. The present invention also provides the antibacterial, the pharmaceutical composition and the method of making the antibacterial as well as a method of treating a subject infected with a bacterial comprising administration of the antibacterial.Type: GrantFiled: October 26, 2010Date of Patent: June 4, 2013Assignees: Albert Einstein College of Medicine of Yeshiva University, Plant Bioscience LimitedInventors: William R. Jacobs, Jr., Rainer Kalscheuer, Stephen Bornemann, Karl Syson
-
Patent number: 8394388Abstract: Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a mycobacterium. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided are methods of inducing an immune response in a mammal and methods of making a recombinant mycobacterium using the nlaA gene or the nuoG gene.Type: GrantFiled: January 12, 2006Date of Patent: March 12, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Steven A. Porcelli, Volker Briken, Miriam Braunstein
-
Publication number: 20120141533Abstract: Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant mycobacterium, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal.Type: ApplicationFiled: March 10, 2008Publication date: June 7, 2012Inventors: William R. Jacobs, JR., Kari Sweeney, Dee Dao, Steven A. Porcelli, John Chan, Tsungda Hsu
-
Patent number: 8101191Abstract: Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not Mycobacterium tuberculosis or Mycobacterium smegmatis. Additionally provided are methods of inducing an immune response in a mammal and methods of inducing an immune response to a pathogenic mycobacterium in a human using the above mycobacterial mutants.Type: GrantFiled: January 11, 2007Date of Patent: January 24, 2012Assignees: Albert Einstein College of Medicine of Yeshiva University, The University of North Carolina at Chapel HillInventors: William R. Jacobs, Jr., Steven A. Porcelli, Miriam Braunstein
-
Patent number: 8084041Abstract: Methods of treating a mammal that is deficient in CD4+ and/or CD8+ lymphocytes are provided. The methods comprise inoculating the mammal with an attenuated mycobacterium in the M. tuberculosis complex. In these methods, the mycobacterium comprises two deletions, wherein a virulent mycobacterium in the M. tuberculosis complex having either deletion exhibits attenuated virulence. Use of these mycobacteria for the manufacture of a medicament for the treatment of mammals deficient in CD4+ and/or CD8+ lymphocytes is also provided.Type: GrantFiled: January 23, 2004Date of Patent: December 27, 2011Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Tsungda Hsu, Vasan Sambandamurthy, Sheldon Morris, Stoyan Bardarov, Svetoslav Bardarov, legal representative
-
Patent number: 7998471Abstract: Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are Mycobacterium smegmatis expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.Type: GrantFiled: January 11, 2006Date of Patent: August 16, 2011Assignees: Albert Einstein College of Medicine of Yeshiva University, Beth Israel Deaconess Medical Center, Inc., Duke UniversityInventors: William R. Jacobs, Jr., Norman L. Letvin, Mark Cayabyab, Barton F. Haynes, Hua-Xin Liao, Jae-Sung Yu, Avi-Hai Hovav
-
Publication number: 20110124593Abstract: The present invention provides methods for determining a putative antibacterial, the methods comprising determining whether the putative antibacterial inhibits GlgE or Rv3032. The present invention also provides the antibacterial, the pharmaceutical composition and the method of making the antibacterial as well as a method of treating a subject infected with a bacterial comprising administration of the antibacterial.Type: ApplicationFiled: October 26, 2010Publication date: May 26, 2011Inventors: William R. Jacobs, JR., Rainer Kalscheuer, Stephen Bornemann, Karl Syson
-
Patent number: 7939089Abstract: Provided are mycobacteria comprising a recombinant gene operably liked to a mammalian promoter that directs expression of the recombinant gene from a mammalian cell. Also provided are mammalian cells comprising the above mycobacteria. Additionally provided are mycobacterial plasmids capable of replication in a mycobacterium. Further provided are methods of expressing a recombinant gene in a mammalian cell.Type: GrantFiled: January 12, 2006Date of Patent: May 10, 2011Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Glenn J. Fennelly
-
Publication number: 20100297185Abstract: Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a mycobacterium. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided are methods of inducing an immune response in a mammal and methods of making a recombinant mycobacterium using the nlaA gene or the nuoG gene.Type: ApplicationFiled: January 12, 2006Publication date: November 25, 2010Inventors: William R. Jacobs, JR., Steven A. Porcelli, Volker Briken, Miriam Braunstein
-
Patent number: 7758874Abstract: Non-naturally occurring mycobacteria in the Mycobacterium tuberculosis complex are provided. These mycobacteria have a deletion of an RD1 region or a region controlling production of a vitamin, and exhibit attenuated virulence in a mammal when compared to the mycobacteria without the deletion. Also provided are non-naturally occurring mycobacteria that have a deletion of a region controlling production of lysine, and mycobacteria comprising two attenuating deletions. Vaccines comprising these mycobacteria are also provided, as are methods of protecting mammals from virulent mycobacteria using the vaccines. Also provided are methods of preparing these vaccines which include the step of deleting an RD1 region or a region controlling production of a vitamin or the amino acids leucine and lysine from a mycobacterium in the M. tuberculosis complex. Embodiments of these mycobacteria, vaccines and methods, encompassing mycobacteria comprising a leucine auxotrophy and a pantothenate auxotrophy, are also provided.Type: GrantFiled: April 19, 2005Date of Patent: July 20, 2010Assignees: Albert Einstein College of Medicine of Yeshiva University, President and Fellows of Harvard CollegeInventors: William R. Jacobs, Jr., Barry Bloom, Mary K. Hondalus, Samantha Sampson, Vasan Sambandamurthy
-
Publication number: 20090110696Abstract: Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not Mycobacterium tuberculosis or Mycobacterium smegmatis. Additionally provided are methods of inducing an immune response in a mammal and methods of inducing an immune response to a pathogenic mycobacterium in a human using the above mycobacterial mutants.Type: ApplicationFiled: January 11, 2007Publication date: April 30, 2009Inventors: William R. Jacobs, JR., Steven A. Porcelli, Miriam Braunstein
-
Patent number: 6821769Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.Type: GrantFiled: July 31, 2001Date of Patent: November 23, 2004Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: David Alland, Barry R. Bloom, William R. Jacobs, Jr.
-
Patent number: 6752994Abstract: A mutated mycobacterium selected from the class consisting of mutated M. bovis-BCG, mutated M. tuberculosis, and mutated M. leprae. The mutation of M. bovis-BCG, M. tuberculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.Type: GrantFiled: July 3, 2001Date of Patent: June 22, 2004Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Barry Bloom, Ganjam V. Kalpana, Jeffrey D. Cirillo, Ruth McAdam